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Abstract Viscosupplementation refers to the concept of
synovial ﬂuid replacement with intra-articular injections of
hyaluronic acid (HA) for the relief of pain associated with
osteoarthritis (OA). Intra-articular viscosupplementation
was approved by the Food and Drug Administration (FDA)
in 1997. It is currently indicated only for the treatment of
pain associated with knee OA. However, OA can occur in
several of the weight-bearing joints of the foot and ankle.
Ankle OA produces chronic disability that directly impacts
the quality of life. There is only limited published literature
relating to the use of HA in the ankle. This paper will
review the authors’ experience, indications, clinical out-
comes, and complications of viscosupplementation therapy
in patients with ankle OA.
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Introduction
Osteoarthritis (OA) is a common progressive degenerative
joint disease with multiple etiologies, but similar biological,
morphological, and clinical outcomes [1, 2]. Individuals
with OA might suffer from pain, muscle weakness, loss of
joint range of motion, and increasing disability. The disease
process of OA is characterized by the progressive erosion of
articular cartilage, leading to joint space narrowing,
subchondral sclerosis, subchondral cysts, synovial inﬂam-
mation, and marginal osteophyte formation [3]. Traditional
treatments for OA include simple analgesics, nonsteroidal
anti-inﬂammatory drugs (NSAIDs), intra-articular cortico-
steroid injections, physiotherapy, activity modiﬁcation,
weightreduction,orthotics,andsurgery[4].Priortosurgical
management of OA, which is expensive, painful, and not
risk-free, all other treatment options should be fully exploi-
ted. Taking into consideration that chronic use of some oral
painmedicationsmaybecontraindicated,alocallydelivered
therapy with no known drug interactions and an excellent
safety proﬁle is a valuable treatment option for patients.
There has been increasing interest and scientiﬁc inves-
tigation of intra-articular injection of hyaluronic acid (HA)
for the treatment of OA over the past 2 decades. Creamer
and Hochberg presented the treatment protocol of OA and
they stated that intra-articular HA played an important role
[1]. HA is a high molecular weight polysaccharide and is
an important component of synovial ﬂuid and extracellular
matrix of articular cartilage. It contributes to the elasticity
and viscosity of synovial ﬂuid. HA acts as a ﬂuid shock
absorber and it helps to maintain the structural and func-
tional characteristics of the cartilage matrix. It also inhibits
the formation and release of prostaglandins, induces pro-
teoglycan aggregation and synthesis, and modulates the
inﬂammatory response [5, 6]. Any degradation of HA is
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damage. OA leads to a reduction in average molecular size
and concentration of HA in the synovial ﬂuid [6–8].
According to Balazs and coworkers [9, 10], the injection of
HA into osteoarthritic joints could restore the viscoelas-
ticity of the synovial ﬂuid, augment the ﬂow of joint ﬂuid,
normalize endogenous hyaluronate synthesis, inhibit hyal-
uronate degradation, reduce joint pain, and improve joint
function.
Viscosupplementation with intra-articular HA was
approved by the Food and Drug Administration (FDA) in
1997. The American College of Rheumatology guidelines
for the treatment of knee OA include the use of visco-
supplementation [11]. The Orthopedic Consensus
Conference made similar recommendations on the use of
HA for the treatment of knee OA [12]. There are ﬁve
injectable forms of HA approved by the United States FDA
including Hyalgan, Supartz, Orthovisc, Synvisc, and Eu-
ﬂexxa. Each of these HA products differ in their origin,
method of production, molecular weight, dosing instruc-
tions, biologic characteristics, and possibly clinical
outcomes (Table 1). There is no consistent evidence from
well-controlled clinical studies that documents the superior
efﬁcacy of one product over another.
Theoretically viscosupplementation is an approach that
should apply to all synovial joints. Off-label use in
degenerative arthritis of the hip, ankle, shoulder, and car-
pometacarpal joint of the thumb seems to be increasing and
a number of recent studies have attempted to evaluate its
efﬁcacy in joints other than the knee [13–23]. The purpose
of this article was to review the authors’ experience,
indications, clinical outcomes, and complications of
viscosupplementation therapy in patients with ankle OA.
Indications
Treatment with HA is indicated for patients who are
functionally limited due to osteoarthritic pain and who
have failed to respond adequately to standard pharmaco-
logic and nonpharmacologic treatment options, those who
have gastrointestinal or renal intolerance to NSAIDs, and
those who wish to postpone surgical intervention or are
poor candidates for surgery.
Intra-articular injections of HA are contraindicated in
patients with known hypersensitivity to HA preparations,
avian proteins, feather and egg products, and those with
active skin disease or infections in the area of the injection
site. Patients with substantial venous or lymphatic stasis in
the legs, bleeding disorder or treatment with anticoagulants
are relatively contraindicated. HA is not recommended to
pregnant women, lactating women, and children under 18,
because the safety and effectiveness have not been
established.
The ideal candidate for intra-articular HA has yet to be
clearly deﬁned. We reported the results of a controlled
study that patients with Kellgren-Lawrence grade I and II
ankle OA had good response to viscosupplementation
(grade 1, doubtful narrowing of joint space and possible
osteophytic lipping; grade 2, deﬁnite osteophytes and
possible narrowing of joint space) [16, 24]. This suggested
that viscosupplementation was effective in mild to mod-
erate ankle OA. Whether severe cases would likely respond
to viscosupplementation remained unknown. Theoretically,
patients with severe OA might have a poor and shorter
response. Because the numbers of patients studied were
relatively small, the results were not analyzed on the basis
of disease severity, cause of OA, or preinjection functional
levels. These factors might have a role in determining the
candidates who would beneﬁt most from this treatment and
might help determine the best overall treatment plan.
Currently, we are recruiting patients with higher X-ray
severity grades in a clinical trial to see whether intra-
articular HA injections can improve ankle pain and func-
tion in severely obliterated ankle joints. As the treatment
group increases, hopefully we could better elucidate
favorable patient response factors and identify patients who
would beneﬁt most from ankle viscosupplementation.
Table 1 Characteristics of ﬁve hyaluronans
Product Origin (method of production) Molecular
weight (kd)
Amount per
injection (ml)
Active ingredients per
injection
Number of injections
per cycle
Hylagan Rooster combs (naturally derived) 500–730 2 20 mg sodium hyaluronate 3 or 5 weekly
Supartz Rooster combs (naturally derived) 620–1170 2.5 25 mg sodium hyaluronate 5 weekly
Orthovisc Rooster combs (naturally derived) 1000–2900 2 30 mg sodium hyaluronate 3 or 4 weekly
Synvisc Rooster combs (chemically
modiﬁed
or cross-linked)
80%: 6000; 20%:
[6000
2 16 mg sodium hyaluronate
derivative
3 weekly
Euﬂexxa Bacterial fermentation (naturally
derived)
2600–3400 2 20 mg sodium hyaluronate 3 weekly
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To date there is only limited published literature on vi-
scosupplementation therapy for ankle OA. Two recent
studies seem to show efﬁcacy on ankle pain and function
(Table 2)[ 15, 16]. Salk et al. performed a randomized,
double-blind, saline solution-controlled trial of intra-artic-
ular injection of sodium hyaluronate for the treatment of
ankle OA. Both groups had signiﬁcant improvement in the
ankle osteoarthritis score at 6 months. However, more of
the patients in the hyaluronate group had [30 points of
improvement on the ankle osteoarthritis score as compared
with the baseline value [15]. This is the ﬁrst controlled
study to show a beneﬁt with HA in the treatment of ankle
OA and is consistent with previous published studies using
HA in the knee.
Our group performed a prospective, controlled study in
patients with unilateral ankle OA and we concluded simi-
larly that a regimen of 5 weekly intra-articular injection of
sodium hyaluronate was safe and efﬁcacious in the areas of
pain and ankle function [16]. The patients’ satisfaction rate
was high with only relatively few local adverse events.
These effects were rapid at 1 week post the ﬁfth injection
and could last for 6 months or more. One limitation in this
trial includes the absence of a control group, thus the
placebo effects associated with joint injections per se were
not analyzed.
Complications
The safety of viscosupplementation has been well docu-
mented in clinical trials and practice. Because there are no
known hyaluronate–medication interactions, it is a good
option for patients on multiple medications, particularly the
elderly. Mild injection-site pain and swelling are the most
common adverse events in the injected joints. These
reactions are usually transient, lasting 1 or 2 days and
generally respond well to local modalities and NSAIDs.
Other adverse events included rash, muscle cramps, diz-
ziness, nausea, headache, local ecchymosis, and pruritus.
The overall incidence of adverse reactions has been
reported to be approximately 1–4% per injection [25–30].
Rare cases of calcium pyrophosphate dehydrate arthritis or
pseudogout ﬂares after both sodium hyaluronate and Syn-
visc have been reported [31]. There is growing evidence
that Synvisc may be associated with an adverse event
termed pseudosepsis or a severe acute inﬂammatory reac-
tion [32–34]. Pseudosepsis presents as a severe
inﬂammatory process of the joint, with a large effusion,
and signiﬁcant pain occurring within 1 to 3 days of the
injection. It requires symptomatic treatment, including use
of modalities, activity modiﬁcation, analgesics, and NSA-
IDs. Once infection has been excluded, intra-articular
steroids may be of value [32, 34].
No systemic adverse events were reported in the litera-
ture relating to ankle viscosupplementation. In the study by
Salk et al., injection site pain was noted in 5 (29%) of the 17
patients including 3 in HA group and 2 in the saline solution
group, with no signiﬁcant difference between the groups.
This injection site pain typically lasted no more than 3 days.
In our ankle OA trial, we reported that local pain and
erythema at the injection site occurred in 5 of 75 patients. It
was mild and resolved within 48 h without sequela in all
cases. The adverse reaction rate was 5.3% per injection and
6.7% per patient. The occurrence of adverse events was
Table 2 Clinical trials of
viscosupplementation in ankle
OA
Author
date
Viscosupplement Study patients
in two different
locations
Outcome measures Outcomes
Salk et al.
(2006)
[15]
Hyalgan
(ﬁve injections)
1 ml per injection
17
9H A
8 placebo
AOS
WOMAC pain domain
Ankle ROM
QOL (EQ-5D, SF-12)
Rescue medication table
count
Safe and efﬁcacious at
6 months
Saline solution group
also demonstrated a
signiﬁcant clinical
beneﬁt, albeit to a
lesser degree
Sun et al.
(2006)
[16]
Supartz (ﬁve
injections)
2.5 ml per
injection
75
75 HA
No placebo
AOS
AOFAS ankle/hindfoot score
Ankle ROM
Patients’ global satisfaction
Rescue medication table
count
Safe and efﬁcacious,
effects rapid at
1 week post the ﬁfth
injection, lasting for
6 months or more
High patients’
satisfaction rate.
Signiﬁcant reduction in
medication
consumption
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injections without any reaction previously, and sometimes
they did not occur in subsequent injections. Interestingly, we
found that local adverse reactions did not predict treatment
failure.Allofthesepatientreceivedsubsequentinjectionsand
they still improved clinically and reported high satisfaction.
Injection technique
Intra-articular injection of the ankle joint is easy to perform
and requires no radiologic guidance.
We position the patient in the supine position, with the
knee ﬂexed and the foot ﬂat on the plinth. The ankle is
placed in a degree of plantarﬂexion, which opens the
anterior aspect of the joint. We identify the space between
the anterior border of the medial malleolus and the medial
border of the tibialis anterior tendon and palpate this space
for the articulation of the talus and tibia to locate a suitable
entry point into the ankle joint. An alternative point of
entry may also be made at the upper, inner aspect of either
malleolus. The injections are performed in aseptic condi-
tions. We insert an 18–22 G needle into the identiﬁed space
and direct posterolaterally to run parallel to the upper
surface of the talus, which is slightly convex (Figs. 1 and
2). Joint effusion, if present, should be aspirated before
injection to prevent dilution of the viscosupplement.
Excessive weight bearing and strenuous activity are dis-
couraged for 48 h after each injection.
Further studies needed
Despite the fact that HA has been proposed as a useful
treatment of symptomatic knee OA, its role in the treatment
of ankle OA is still not clear, due fundamentally to the
dearth of studies and to the methodological limitations of
those that have been published. The exact mechanisms of
viscosupplementation action on osteoarthritic joints are
uncertain. Although recent attention has focused on the
disease-modifying potential of HA, especially the chon-
droprotective mechanism, deﬁnitive evidence is still
lacking. We believe that HA can be used as an adjunct
therapy, after failure of one or more courses of oral pain
medications, or perhaps as a ﬁrst choice in the treatment of
ankle OA before prescription of pain medications. It is
important to understand the distinct mechanisms of HA to
help appropriately place viscosupplementation into the
physicians’ treatment algorithms.
Future studies regarding optimal dosing regimen; opti-
mal number of injections in a course of treatment;
favorable prognostic factors; effectiveness and safety of
repeated courses of therapy; different concentration and
molecular weight options for ankle viscosupplementation;
as well as the biochemical, morphologic, and histopatho-
logic effects on cartilage are warranted. Cost-effectiveness
needs to be addressed. The robust placebo effect deserves
special attention when critically interpreting outcome data.
Comparison studies or combination therapies with other
treatment options, such as intra-articular steroid injections,
NSAIDs, and therapeutic exercise, are also needed.
We hoped that this review will stimulate interest in
research to assess the potential role of viscosupplementa-
tion in treating ankle OA and more research is needed to
demonstrate its true beneﬁt before this treatment option
will be fully accepted.
Conclusion
The published data suggest that viscosupplementation may
be a safe and effective method in the treatment of ankle Fig. 1 Ankle joint injection
Fig. 2 Ankle joint injection
Curr Rev Musculoskelet Med (2009) 2:78–82 81OA. However, the limited number of patients with ankle
OA enrolled in clinical trials precludes any deﬁnitive
conclusion about its safety and efﬁcacy. To date, ankle
viscosupplementation should only be used under careful
supervision by the clinician. Many uncertainties on the use
of HA remain. More studies with larger patient populations
are required before viscosupplementation should be inclu-
ded into the treatment paradigm for patients with ankle
OA.
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